Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Karol M, Córdoba"'
Autor:
Miriam Longo, Erika Paolini, Marica Meroni, Daniel Jericó, Karol M. Córdoba, Michele Battistin, Stefano Gatti, Elena Di Pierro, Antonio Fontanellas, Paola Dongiovanni
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 17, Iss 3, Pp 511-514 (2024)
Externí odkaz:
https://doaj.org/article/367cbd0a2ee74277ae4cfa046fab40bb
Autor:
Miriam Longo, Daniel Jericó, Karol M. Córdoba, José Ignacio Riezu-Boj, Raquel Urtasun, Isabel Solares, Ana Sampedro, María Collantes, Ivan Peñuelas, María Jesús Moreno-Aliaga, Matías A. Ávila, Elena Di Pierro, Miguel Barajas, Fermín I. Milagro, Paola Dongiovanni, Antonio Fontanellas
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 15, p 11938 (2023)
Acute intermittent porphyria (AIP) is a metabolic disorder caused by mutations in the porphobilinogen deaminase (PBGD) gene, encoding the third enzyme of the heme synthesis pathway. Although AIP is characterized by low clinical penetrance (~1% of PBG
Externí odkaz:
https://doaj.org/article/4f05cfbbec6f45b288b2bf102e5b5aba
Autor:
Daniel Jericó, Karol M. Córdoba, Lei Jiang, Caroline Schmitt, María Morán, Ana Sampedro, Manuel Alegre, María Collantes, Eva Santamaría, Estíbaliz Alegre, Corinne Culerier, Ander Estella-Hermoso de Mendoza, Julen Oyarzabal, Miguel A. Martín, Iván Peñuelas, Matías A. Ávila, Laurent Gouya, Paolo G.V. Martini, Antonio Fontanellas
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 25, Iss , Pp 207-219 (2021)
Variegate porphyria (VP) results from haploinsufficiency of protoporphyrinogen oxidase (PPOX), the seventh enzyme in the heme synthesis pathway. There is no VP model that recapitulates the clinical manifestations of acute attacks. Combined administra
Externí odkaz:
https://doaj.org/article/f0e88f862dcd434c9fb48ea42beb448a
Autor:
Isabel Solares, Daniel Jericó, Karol M. Córdoba, Montserrat Morales-Conejo, Javier Ena, Rafael Enríquez de Salamanca, Antonio Fontanellas
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 51 (2022)
Porphobilinogen deaminase (PBGD) haploinsufficiency (acute intermittent porphyria, AIP) is characterized by neurovisceral attacks associated with high production, accumulation and urinary excretion of heme precursors, δ-aminolevulinic acid (ALA) and
Externí odkaz:
https://doaj.org/article/2113cb2bb1924aec82362266dc98898c
Autor:
Daniel Jericó, Karol M. Córdoba, Ana Sampedro, Lei Jiang, Gilles Joucla, Charlotte Cabanne, José Luis Lanciego, Paolo G. V. Martini, Pedro Berraondo, Matías A. Ávila, Antonio Fontanellas
Publikováno v:
Life, Vol 12, Iss 11, p 1858 (2022)
Rare diseases, especially monogenic diseases, which usually affect a single target protein, have attracted growing interest in drug research by encouraging pharmaceutical companies to design and develop therapeutic products to be tested in the clinic
Externí odkaz:
https://doaj.org/article/e85dc083829242d0a9443dcdb8a9237a
Autor:
Sheila Maestro, Karol M. Córdoba, Cristina Olague, Josepmaria Argemi, Matías A. Ávila, Gloria González-Aseguinolaza, Cristian Smerdou, Antonio Fontanellas
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 137, Iss , Pp 111384- (2021)
Antiviral agents with different mechanisms of action could induce synergistic effects against SARS-CoV-2 infection. Some reports suggest the therapeutic potential of the heme oxygenase-1 (HO-1) enzyme against virus infection. Given that hemin is a na
Externí odkaz:
https://doaj.org/article/06c7ce1a5c244222b6eb2ffd0ababdb7
Autor:
Diego Vera‐Yunca, Karol M. Córdoba, Zinnia P. Parra‐Guillen, Daniel Jericó, Antonio Fontanellas, Iñaki F. Trocóniz
Publikováno v:
British Journal of Pharmacology. 179:3815-3830
Acute intermittent porphyria (AIP) is a rare disease caused by a genetic mutation in the hepatic activity of the porphobilinogen-deaminase. We aimed to develop a mechanistic model of the enzymatic restoration effects of a novel therapy based on the a
Autor:
Miguel A. Martín, Karol M. Córdoba, Antonio Fontanellas, Corinne Culerier, Eva Santamaría, Ana Sampedro, M J Morán, María Collantes, Matías A. Avila, Laurent Gouya, Manuel Alegre, Estibaliz Alegre, Caroline Schmitt, Julen Oyarzabal, Lei Jiang, Paolo Martini, Ander Estella-Hermoso de Mendoza, Iván Peñuelas, Daniel Jericó
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 25, Iss, Pp 207-219 (2021)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Variegate porphyria (VP) results from haploinsufficiency of protoporphyrinogen oxidase (PPOX), the seventh enzyme in the heme synthesis pathway. There is no VP model that recapitulates the clinical manifestations of acute attacks. Combined administra
Autor:
Karol M, Córdoba, Daniel, Jericó, Ana, Sampedro, Lei, Jiang, María J, Iraburu, Paolo G V, Martini, Pedro, Berraondo, Matías A, Avila, Antonio, Fontanellas
Publikováno v:
International review of cell and molecular biology. 372
Inborn errors of metabolism (IEM) encompass a group of monogenic diseases affecting both pediatric and adult populations and currently lack effective treatments. Some IEM such as familial hypercholesterolemia or X-linked protoporphyria are caused by
Autor:
Karol M. Córdoba, Irantzu Serrano-Mendioroz, Daniel Jericó, María Merino, Lei Jiang, Ana Sampedro, Manuel Alegre, Fernando Corrales, María J. Garrido, Paolo G. V. Martini, José Luis Lanciego, Jesús Prieto, Pedro Berraondo, Antonio Fontanellas
Publikováno v:
Science Translational Medicine. 14
Correction of enzymatic deficits in hepatocytes by systemic administration of a recombinant protein is a desired therapeutic goal for hepatic enzymopenic disorders such as acute intermittent porphyria (AIP), an inherited porphobilinogen deaminase (PB